Odyssey's 146-patient phase 2a trial will pair OD-001 with vedolizumab, targeting both innate and adaptive immune drivers of ulcerative colitis.
Feature|Events|October 1, 2026
- BioPharm International September October 2026
- Volume 39
- Issue 5
Personalizing Dendritic Cell Vaccines to Prevent Cancer Recurrence
Author(s)Keith L. Knutson, Feliza Mirasol
Keith Knutson, PhD, of Mayo Clinic explains why vaccine manufacturing speed and cost will determine real-world scalability.
Advertisement
Advertisement
Keith L. Knutson, PhD, of Mayo Clinic discusses how personalized dendritic cell vaccines target tumor heterogeneity, build lasting immune memory, and overcome tumor-driven immune suppression. He outlines why manufacturing speed and cost will shape adoption and why pairing vaccines with checkpoint inhibitors offers the most promising path toward durable cancer control.
Related to this article
MT027, T-MAXIMUM's B7-H3 CAR-T therapy, earns a second FDA-cleared phase 2 trial, now testing lung and breast cancer brain metastases.
Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.
Caribou is halting vispa-cel and CB-011, allogeneic CAR-T therapies that showed up to 92% response rates, citing a difficult financing environment.
Mirikizumab (Omvoh) achieved comprehensive disease control in 27.7% of UC patients and deep remission in 20.4% with Crohn disease at 1 year.
As ArsenalBio, TScan, Bristol Myers Squibb, and others abandon ex vivo programs for in vivo engineering, early clinical data and platform differences point to both the promise and the unresolved safety, manufacturing, and regulatory questions of generating CAR-T cells inside the body.
BNT113 plus pembrolizumab failed to significantly extend progression-free survival in a 285-patient HPV16-positive head and neck cancer trial.
Gilead will develop up to three PRO-XTEN T-cell engagers discovered by Vir Biotechnology for solid tumors in a deal worth up to $1.74 billion.
Advertisement
Advertisement